Posts | Comments

India Offers an Array of Opportunities for NIPT Market Growth

Contact Us
Author
G-199, Sector 63
Noida
Uttar Pradesh 201301 
India
Phone:1204224700
Fax:1204224700
press@rncos.com

India witnessed around 24 Million births in 2015. Though, the mean age of mother at first birth is about 20 years, an increasing number of women in Tier-1 cities are giving preference to their career and are opting for childbearing at a later age, stretching to their 30s. As a result, a rising trend of conception related complications can be observed in Indian cities, which experienced around 80,000-100,000 IVF cycles annually.

With rise in age of mother, there also increases her risk of having a baby suffering from Down’s syndrome. Women at 30 years of age have a 1:900 chance of having a baby with Down’s syndrome, while this risk rises to as high as one in every 85 births for women ageing 40 years. In India, around 19% live births fall in the high-risk group for Down’s syndrome. Another 19% live births have a risk of 1:1,000-1:500 for having Down’s syndrome, making India a country with a high number of people in need for tests that could alert the physicians and pregnant women about the 21 chromosome triploidy status of the fetus, ultimately leading to a better prepared and informed response for delivery of a child with Down’s syndrome.

According to new report by RNCOS, named, “Indian NIPT Market Outlook 2022”, currently, two local players have entered the Indian NIPT market including MedGenome Labs Pvt. Ltd. and Igenomix India. These key players are competing against each other, in order to expand their existing customer base in the Indian market. MedGenome has collaborated with Natera to provide Panorama in India. These local players have developed their own laboratory and infrastructure in India. This not only helps in reducing the time of diagnosis, but also the accuracy as the sample will not have to travel so long.

Moreover, the announcements made by BMC Officials in 2014, has helped local players in making well-established relationships with their customers. As per the BMC rules, genetic testing/pathology centers have to register themselves under the Pre-Conception and Pre-Natal Diagnostic Techniques (PCPNDT) Act, and ensure they followed the rules. The centers that send blood samples abroad or elsewhere in the country should be registered. These measures undertaken are enforcing the local players to set up their labs in India itself, and simultaneously increasing the shares of the local players.

Though India represents a huge potential market, it needs a carefully laid out strategy for the penetration.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM856.htm

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

ABOUT RNCOS

RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.

Leave a Reply